Shares of Summit Therapeutics SMMT surged 56% on Monday after it reported additional results from the phase III HARMONi-2 study, which compared its investigational antibody ivonescimab (SMT112) with ...
Source LinkShares of Summit Therapeutics SMMT surged 56% on Monday after it reported additional results from the phase III HARMONi-2 study, which compared its investigational antibody ivonescimab (SMT112) with ...
Source Link
Comments